Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR -mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial

(2017) Yi-Long Wu et al.   LANCET ONCOLOGY

Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers

(2017) Helena A. Yu et al.   LUNG CANCER

ABCG2-overexpressing H460/MX20 cell xenografts in athymic nude mice maintained original biochemical and cytological characteristics

(2017) Wei Zhang et al.   Scientific Reports

Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells

(2017) Majid Momeny et al.   Scientific Reports

A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors

(2016) Emiliano Calvo et al.   CLINICAL CANCER RESEARCH

ABCG2 inhibition as a therapeutic approach for overcoming multidrug resistance in cancer

(2016) Maryam Hosseini Hasanabady et al.   JOURNAL OF BIOSCIENCES

A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck

(2012) A. R. Abdul Razak et al.   ANNALS OF ONCOLOGY

Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein

(2012) Wen-jing Zhou et al.   BRITISH JOURNAL OF PHARMACOLOGY

Loperamide, an FDA-Approved Antidiarrhea Drug, Effectively Reverses the Resistance of Multidrug Resistant MCF-7/MDR1 Human Breast Cancer Cells to Doxorubicin-Induced Cytotoxicity

(2012) Yanfei Zhou et al.   CANCER INVESTIGATION

Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

(2012) Suresh S. Ramalingam et al.   JOURNAL OF CLINICAL ONCOLOGY

Apatinib (YN968D1) enhances the efficacy of conventional chemotherapeutical drugs in side population cells and ABCB1-overexpressing leukemia cells

(2011) Xiu-zhen Tong et al.   BIOCHEMICAL PHARMACOLOGY

Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2

(2009) Chun-ling Dai et al.   CANCER LETTERS

ABC Transporters as Potential Targets for Modulation of Drug Resistance

(2009) L. Gatti et al.   MINI-REVIEWS IN MEDICINAL CHEMISTRY

Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1®

(2008) Robert W. Robey et al.   BIOCHEMICAL PHARMACOLOGY

Synthesis and structure–activity relationship studies on tryprostatin A, an inhibitor of breast cancer resistance protein

(2008) Hiteshkumar D. Jain et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2

(2008) C.-l. Dai et al.   CANCER RESEARCH